Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
By Chris WackMerck said it saw positive topline results for its Phase 2b/3 trial for remigromig in adults with diabetic macular edema.The pharmaceutical company said the trial, the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig met its primary endpoint.Remigromig is…
Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 week